Clinical Study to Evaluate the Effects of the Complement C5 Inhibitor Ravulizumab on Serum Neurofilament Light Chain (sNfL) and Glial Fibrillary Acidic Protein (sGFAP) Levels in Patients With Aquaporin-4-Positive (AQP4-Ab+) Neuromyelitis Optica Spectrum Disorder (NMOSD)
Clinical trial NCT06903130 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06903130
- Sponsor
- National and Kapodistrian University of Athens
- Status
- NOT_YET_RECRUITING
- Study type
- OBSERVATIONAL
- Start date
- 2025-09-01
- Primary completion
- 2027-09-01
- Enrollment
- 40
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.